X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2937) 2937
life sciences & biomedicine (2776) 2776
animals (1998) 1998
male (1783) 1783
humans (1513) 1513
glucosides - pharmacology (1189) 1189
pharmacology & pharmacy (1123) 1123
rats (1012) 1012
female (870) 870
glucosides - administration & dosage (842) 842
glucosides - therapeutic use (824) 824
mice (673) 673
diabetes mellitus, type 2 - drug therapy (609) 609
chemistry (569) 569
rats, sprague-dawley (540) 540
physical sciences (530) 530
glucosides - chemistry (462) 462
middle aged (462) 462
biochemistry & molecular biology (448) 448
diabetes (445) 445
type 2 diabetes (432) 432
glucosides - pharmacokinetics (427) 427
glucose (391) 391
dose-response relationship, drug (384) 384
hypoglycemic agents - therapeutic use (377) 377
adult (371) 371
analysis (371) 371
chemistry, medicinal (363) 363
endocrinology & metabolism (341) 341
administration, oral (327) 327
glucosides - adverse effects (327) 327
sodium-glucose transporter 2 - antagonists & inhibitors (326) 326
benzhydryl compounds - therapeutic use (316) 316
glucosides (300) 300
research (288) 288
care and treatment (286) 286
rats, wistar (286) 286
aged (285) 285
treatment outcome (274) 274
disease models, animal (271) 271
rodents (261) 261
hypoglycemic agents - administration & dosage (260) 260
plant sciences (255) 255
pharmacokinetics (248) 248
diabetes mellitus (242) 242
plant extracts - pharmacology (237) 237
glucosides - blood (235) 235
health aspects (231) 231
hypoglycemic agents - adverse effects (228) 228
inflammation (225) 225
dextrose (223) 223
benzhydryl compounds - administration & dosage (222) 222
blood glucose - drug effects (220) 220
chromatography, high pressure liquid (215) 215
blood glucose - metabolism (212) 212
chemistry, analytical (212) 212
dapagliflozin (210) 210
apoptosis (205) 205
food science & technology (204) 204
glucosides - metabolism (201) 201
oxidative stress (200) 200
diabetes mellitus, type 2 - blood (199) 199
glucosides - isolation & purification (195) 195
benzhydryl compounds - adverse effects (194) 194
double-blind method (193) 193
integrative & complementary medicine (193) 193
mice, inbred c57bl (189) 189
cell biology (188) 188
research article (184) 184
mass spectrometry (183) 183
hypoglycemic agents - pharmacology (182) 182
apoptosis - drug effects (181) 181
physiological aspects (180) 180
proteins (180) 180
antioxidants (177) 177
drug therapy, combination (173) 173
signal transduction - drug effects (170) 170
metabolites (169) 169
toxicology (166) 166
chemistry, multidisciplinary (165) 165
pharmacology/toxicology (165) 165
plant extracts - chemistry (165) 165
phenols - pharmacology (163) 163
molecular structure (161) 161
sodium (160) 160
internal medicine (159) 159
chromatography, high pressure liquid - methods (158) 158
metabolism (157) 157
paeoniflorin (157) 157
cells, cultured (156) 156
clinical trials (156) 156
phytotherapy (154) 154
time factors (153) 153
drug therapy (152) 152
biochemical research methods (149) 149
benzhydryl compounds - pharmacology (148) 148
sglt2 inhibitor (148) 148
medicine (147) 147
reproducibility of results (147) 147
studies (144) 144
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3462) 3462
Chinese (112) 112
Japanese (87) 87
German (18) 18
Spanish (7) 7
French (6) 6
Russian (5) 5
Italian (4) 4
Czech (3) 3
Portuguese (2) 2
Danish (1) 1
Hungarian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes (New York, N.Y.), ISSN 1939-327X, 05/2016, Volume 65, Issue 5, pp. 1190 - 1195
...). In both groups, empagliflozin administration raised EGP, lowered... 
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glucose Intolerance - metabolism | Glycosuria - chemically induced | Carbohydrate Metabolism - drug effects | Lipolysis - drug effects | Benzhydryl Compounds - administration & dosage | Humans | Glucagon-Like Peptide 1 - blood | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Glucagon - blood | Glucose Intolerance - blood | Glucose Intolerance - drug therapy | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Time Factors | Glucosides - therapeutic use | C-Reactive Protein - analysis | Benzhydryl Compounds - therapeutic use | Insulin Secretion | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | 3-Hydroxybutyric Acid - blood | Sodium-Glucose Transporter 2 - metabolism | Glucose Intolerance - urine | 3-Hydroxybutyric Acid - agonists | Renal Elimination - drug effects | Sodium-Glucose Transporter 2 Inhibitors | Membrane Transport Modulators - administration & dosage | Diabetes Mellitus, Type 2 - urine | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Algorithms | Glucosides - administration & dosage | 3-Hydroxybutyric Acid - metabolism | Lipid Metabolism - drug effects | Membrane Transport Modulators - therapeutic use | Glucagon - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Energy Metabolism - drug effects | Type 2 diabetes | Care and treatment | Glucagon | Dosage and administration | Triglycerides | Research | Insulin
Journal Article
Journal Article
Clinical therapeutics, ISSN 0149-2918, 2013, Volume 35, Issue 1, pp. A33 - A42
Abstract Background Empagliflozin is an oral, potent, and selective inhibitor of sodium glucose cotransporter 2, inhibition of which reduces renal glucose... 
Internal Medicine | Medical Education | empagliflozin | linagliptin | drug–drug interaction | diabetes | SGLT2 inhibitor | DPP-4 inhibitor | drug-drug interaction | SGLT2 inhibi-tor | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Glucosides - blood | Benzhydryl Compounds - administration & dosage | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Humans | Middle Aged | Dipeptidyl Peptidase 4 - blood | Half-Life | Quinazolines - pharmacokinetics | Male | Metabolic Clearance Rate | Glucosides - pharmacokinetics | Purines - administration & dosage | Benzhydryl Compounds - blood | Young Adult | Hypoglycemic Agents - blood | Kidney - metabolism | Benzhydryl Compounds - adverse effects | Drug Interactions | Hypoglycemic Agents - administration & dosage | Purines - blood | Adult | Quinazolines - administration & dosage | Linagliptin | Purines - adverse effects | Drug Therapy, Combination | Benzhydryl Compounds - pharmacokinetics | Glucosides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - blood | Hypoglycemic Agents - pharmacokinetics | Kidney - drug effects | Drug Administration Schedule | Administration, Oral | Sodium-Glucose Transporter 2 - metabolism | Purines - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Quinazolines - blood | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Cross-Over Studies | Analysis of Variance | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Glucosides - administration & dosage | Models, Biological | Quinazolines - adverse effects | Glucose - metabolism | Hypoglycemic Agents - adverse effects | Germany | Type 2 diabetes | Glucose | Drug interactions | Dextrose | Studies | Confidence intervals | Clinical trials | Substance abuse treatment | Diabetes | Drug dosages
Journal Article
PloS one, ISSN 1932-6203, 08/2014, Volume 9, Issue 8, p. e103648
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 2017, Volume 6, Issue 6
Journal Article
Biological & pharmaceutical bulletin, ISSN 0918-6158, 2016, Volume 39, Issue 4, pp. 601 - 610
Journal Article